MX2017006016A - Composiciones conjugadas de xten direccionadas y metodos para producir las mismas. - Google Patents

Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.

Info

Publication number
MX2017006016A
MX2017006016A MX2017006016A MX2017006016A MX2017006016A MX 2017006016 A MX2017006016 A MX 2017006016A MX 2017006016 A MX2017006016 A MX 2017006016A MX 2017006016 A MX2017006016 A MX 2017006016A MX 2017006016 A MX2017006016 A MX 2017006016A
Authority
MX
Mexico
Prior art keywords
methods
compositions
conjugate compositions
targeted
making same
Prior art date
Application number
MX2017006016A
Other languages
English (en)
Spanish (es)
Inventor
Yang Fan
Schellenberger Volker
Ding Sheng
THAYER Desiree
Wei Wang Chia-
Original Assignee
Amunix Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Operating Inc filed Critical Amunix Operating Inc
Publication of MX2017006016A publication Critical patent/MX2017006016A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2017006016A 2014-11-11 2015-11-11 Composiciones conjugadas de xten direccionadas y metodos para producir las mismas. MX2017006016A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462078171P 2014-11-11 2014-11-11
US201562119483P 2015-02-23 2015-02-23
US201562211378P 2015-08-28 2015-08-28
PCT/US2015/060230 WO2016077505A2 (en) 2014-11-11 2015-11-11 Targeted xten conjugate compositions and methods of making same

Publications (1)

Publication Number Publication Date
MX2017006016A true MX2017006016A (es) 2017-06-19

Family

ID=55955256

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006016A MX2017006016A (es) 2014-11-11 2015-11-11 Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.

Country Status (14)

Country Link
US (1) US20180125988A1 (cg-RX-API-DMAC7.html)
EP (1) EP3218390A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018500049A (cg-RX-API-DMAC7.html)
KR (1) KR20170083095A (cg-RX-API-DMAC7.html)
CN (1) CN107207564A (cg-RX-API-DMAC7.html)
AU (1) AU2015346330A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017009951A2 (cg-RX-API-DMAC7.html)
CA (1) CA2964968A1 (cg-RX-API-DMAC7.html)
EA (1) EA201790871A1 (cg-RX-API-DMAC7.html)
IL (1) IL251823A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017006016A (cg-RX-API-DMAC7.html)
PH (1) PH12017500866A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201703803WA (cg-RX-API-DMAC7.html)
WO (1) WO2016077505A2 (cg-RX-API-DMAC7.html)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
JP7015244B2 (ja) 2016-03-22 2022-02-02 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化t細胞二重特異性分子
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
AU2017364818C1 (en) 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
CA3041279A1 (en) 2016-11-28 2018-05-31 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
MD3558391T2 (ro) 2016-12-23 2022-05-31 Immunogen Inc Imunoconjugate care țintesc ADAM9 și procedee de utilizare a acestora
BR112019012950A2 (pt) 2016-12-23 2019-11-26 Macrogenics, Inc. molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
SG11201906319XA (en) 2017-01-20 2019-08-27 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
CA3053275A1 (en) * 2017-02-10 2018-08-16 Dragonfly Therapeutics, Inc. Proteins binding psma, nkg2d and cd16
SG11201909064RA (en) * 2017-03-30 2019-10-30 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
WO2018213335A1 (en) * 2017-05-16 2018-11-22 Scalmibio, Inc. Activatable antibodies and methods of use thereof
WO2019023164A1 (en) * 2017-07-24 2019-01-31 The Board Of Trustees Of The Leland Stanford Junior University COMPOSITIONS AND METHODS FOR INDUCING PROTEIN FUNCTION
JP7801095B2 (ja) 2017-08-01 2026-01-16 エイビー セラピューティクス インコーポレイテッド 二重特異性抗体およびその使用
KR20200089312A (ko) * 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
KR20250134208A (ko) 2017-11-28 2025-09-09 추가이 세이야쿠 가부시키가이샤 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
EP3717019A4 (en) 2017-11-28 2021-09-22 Board of Regents of the University of Nebraska RADIOPHARMACEUTICALS AND METHOD OF USE THEREOF
KR20260039804A (ko) * 2017-12-21 2026-03-20 아뮤닉스 파마슈티컬스, 인크. 유리 세그먼트 및 이것을 포함하는 결합 조성물
BR112020023136A2 (pt) 2018-05-14 2021-02-09 Nuvation Bio Inc. compostos de alvo de receptor de hormônio nuclear anticâncer
CN112513081A (zh) 2018-06-14 2021-03-16 生物蛋白有限公司 多重特异性抗体构建体
MX2020014290A (es) 2018-06-22 2021-08-05 Cugene Inc Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
MX2020013466A (es) 2018-06-26 2021-04-19 Immunogen Inc Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
EP3823611A1 (en) * 2018-07-18 2021-05-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
MX2021005048A (es) 2018-10-31 2021-09-08 Bioatla Inc Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
WO2020113036A2 (en) * 2018-11-28 2020-06-04 Promega Corporation Reactive peptide labeling
CN113660956B (zh) 2019-01-28 2024-10-29 Ab诊疗公司 双特异性抗体及其用途
TWI739358B (zh) * 2019-03-25 2021-09-11 免疫功坊股份有限公司 帶有金屬結合區的複合多肽及其分子構建體
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
CN114026127B (zh) 2019-06-11 2024-10-29 生物蛋白有限公司 条件活性抗epcam抗体、抗体片段、其免疫缀合物以及其用途
US12048926B2 (en) * 2019-06-26 2024-07-30 Waters Technologies Corporation Coatings with immobilized affinity ligands and enzymes and use thereof in liquid chromatography assays
KR102793948B1 (ko) 2019-08-07 2025-04-11 맙플렉스 인터내셔널 컴퍼니 리미티드 항체-약물 접합체 및 이의 용도
WO2021041300A2 (en) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4058466A1 (en) 2019-11-13 2022-09-21 Amunix Pharmaceuticals, Inc. Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
CA3163358A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN115943210A (zh) 2020-01-20 2023-04-07 中外制药株式会社 配体结合融合蛋白
PH12022553407A1 (en) * 2020-06-25 2024-04-22 Amunix Pharmaceuticals Inc Her-2 targeted bispecific compositions and methods for making and using the same
CN116583532A (zh) * 2020-06-25 2023-08-11 阿穆尼克斯制药公司 靶向her-2的双特异性组合物以及其制造和使用方法
AU2021326469C1 (en) * 2020-08-11 2026-04-30 Janux Therapeutics, Inc. Cleavable linker compositions and methods
EP4768463A2 (en) * 2020-08-13 2026-07-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibody drug conjugate
CA3193453A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
WO2022178754A1 (en) * 2021-02-25 2022-09-01 Shanghai Allygen Biologics Co., Ltd. Targeting conjugates with therapeutic agents and oligonucleotides and uses thereof
JP2024512392A (ja) 2021-03-08 2024-03-19 イミュノジェン・インコーポレーテッド がんの治療のためのadam9を標的とする免疫抱合体の有効性を増加させるための方法
EP4313991A1 (en) 2021-03-23 2024-02-07 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113215195B (zh) * 2021-04-30 2023-04-11 四川大学 一种在肌源性细胞特异性高表达sia的重组表达载体及其应用
WO2022235585A1 (en) 2021-05-03 2022-11-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
KR20240017024A (ko) * 2021-06-04 2024-02-06 이뮤노젠 아이엔씨 가용성 fr-알파를 이용한 환자의 암 치료
CN117500885A (zh) * 2021-06-10 2024-02-02 罗塞洛公司 具有低热原活性的可交联官能化的明胶
CN116143935A (zh) * 2021-11-22 2023-05-23 杭州翰思生物医药有限公司 重组抗体及其应用
CN114672450B (zh) * 2022-01-26 2022-11-11 中山大学附属第一医院 一种分离纯化卵泡膜细胞的方法
US12405254B2 (en) * 2022-02-18 2025-09-02 Dionex Corporation Low temperature oligosaccharide analytical system and method
WO2023161853A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
CN114965426B (zh) * 2022-05-17 2025-07-11 南京师范大学 一种膜ⅰ型基质金属蛋白酶活性检测方法
WO2024020486A2 (en) * 2022-07-20 2024-01-25 Fuse Biotherapeutics Inc. Receptor tyrosine kinase-like orphan receptor 1 (ror1)-specific vhh antibodies and multispecific antibodies thereof as immune cell engagers
CN118126116A (zh) * 2022-12-01 2024-06-04 核欣(苏州)医药科技有限公司 异二聚体及其放射性医药用途
CN116077686B (zh) * 2022-12-15 2025-06-27 苏州智核生物医药科技有限公司 可酶切Linker及其用途
CN116199747A (zh) * 2022-12-26 2023-06-02 中国医学科学院医药生物技术研究所 一种力达霉素前药、制备方法及其在制备抗肿瘤药物中的应用
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
CN122349537A (zh) 2023-12-01 2026-07-07 阿布林克斯有限公司 识别人血清白蛋白、tcr和肿瘤抗原识别部分的多特异性抗体
CN119033950B (zh) * 2024-08-23 2025-11-11 武汉大学 氧氟沙星或其衍生物与pd-1单克隆抗体偶联物及其应用
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
US20260109746A1 (en) 2024-10-22 2026-04-23 Gilead Sciences, Inc. Cd4-targeted il-15 molecules and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US8383767B2 (en) * 2008-06-27 2013-02-26 Academia Sinica Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain
DK3178835T3 (da) * 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
PE20121539A1 (es) * 2009-06-08 2012-12-06 Amunix Operating Inc Polipeptidos de la hormona de crecimiento y metodos de preparacion
CN104302408B (zh) * 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
US20130316946A1 (en) * 2012-05-24 2013-11-28 Cebix, Inc. Extended recombinant polypeptide-modified c-peptide

Also Published As

Publication number Publication date
KR20170083095A (ko) 2017-07-17
WO2016077505A2 (en) 2016-05-19
EA201790871A1 (ru) 2017-11-30
CA2964968A1 (en) 2016-05-19
CN107207564A (zh) 2017-09-26
BR112017009951A2 (pt) 2017-12-26
JP2018500049A (ja) 2018-01-11
AU2015346330A1 (en) 2017-05-11
IL251823A0 (en) 2017-07-31
EP3218390A2 (en) 2017-09-20
EP3218390A4 (en) 2018-11-21
WO2016077505A3 (en) 2016-07-21
US20180125988A1 (en) 2018-05-10
PH12017500866A1 (en) 2017-11-06
SG11201703803WA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
PH12017500866A1 (en) Targeted xten conjugate compositions and methods of making same
PH12014501924A1 (en) Xten conjugate compositions and methods of making same
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
TW201613958A (en) MIC-1 fusion proteins and uses thereof
MX2009010148A (es) Peptidos ciclicos de proteinas receptor-asociadas (rap).
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
MX353608B (es) Anticuerpo modificado en el que el tema que comprende residuos de cisteina esta ligado, conjugado de farmaco de anticuerpo modificado que comprende el anticuerpo modificado y metodo de produccion para el mismo.
MY187047A (en) Selective pyy compounds and uses thereof
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
WO2014062697A3 (en) Drug delivery conjugates containing unnatural amino acids and methods for using
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
PH12014502766A1 (en) Fibroblast growth factor 21 proteins
ZA202002094B (en) Trispecific proteins and methods of use
MY192248A (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
PE20130648A1 (es) Tratamiento del sindrome de sanfilippo tipo b
MY167804A (en) Treatment of degenerative joint disease
NZ707160A (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
WO2014039074A3 (en) Therapeutic compositions and related methods
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
WO2016205397A3 (en) Target-specific delivery of therapeutic agents
WO2018200814A3 (en) Modified cyclic peptides and therapeutic use thereof